Akari Therapeutics Plc - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Akari Therapeutics Plc on April 26, 2016, reporting events occurring on April 20, 2016. The filing addresses corporate governance changes, specifically the appointment of a new director and adjustments to the Audit Committee.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and compensation arrangements rather than financial performance.
Material Changes
- Director Appointment: David Byrne was appointed as a Class A director effective April 20, 2016, serving until the 2016 annual meeting of shareholders.
- Committee Change: Stuart Ungar, M.D., ceased to be a member of the Audit Committee effective April 20, 2016, with Mr. Byrne serving as his successor.
Compensation and Governance Details
Mr. Byrne received the following compensation arrangements for his services as a non-executive director:
- Initial Equity Grant: An option to purchase 1,300,000 ordinary shares at fair market value, vesting ratably over three years.
- Future Equity Grant: If elected at the 2016 annual meeting, Mr. Byrne is entitled to an annual option to purchase 1,300,000 shares, vesting on the anniversary of the grant.
- Cash Fees: An annual fee of $36,000 (pro-rated for the initial term) and an additional annual fee of $5,000 for Audit Committee service (pro-rated).
- Expenses: Reimbursement for customary business expenses related to Board meetings.
Investor Verification Checklist
- Verify the outcome of the 2016 annual meeting of shareholders regarding Mr. Byrne's election.
- Confirm the total number of shares outstanding to assess the dilution impact of the 1,300,000 share option grants.
- Review the company's latest 10-K or 10-Q for financial metrics not included in this 8-K.